Objective: While the efficacy ofcognitive-behaviour therapy (CBT) for the treatment ofacute unipolar major depression is well-documented, there is almost no data evaluating its utility in the treatment ofbipolar depression. Thispilot study compares the efficacy ofCBTcombined with mood-stabilizerpharmacotherapyfor bipolar depression and CBT alone for unipolar depression.
search on the therapeutics ofdepressive disorders (10) . In addition, although somatic therapies are unquestionably the mainstay of treatment, there are several indications as to the potential utility of a psychosocial intervention in this population, given that all somatic treatments have limitations. For example, although lithium treatment has been demonstrated to confer a 6-fold reduction in suicide compared with no treatment (11), over the long term, lithium protects only one-half ofbipolar patients from recurrence, even under optimal conditions, and most bipolar patients relapse within 2 years (12) . In addition, lithium maintenance therapy has been shown to confer a greater reduction in mania compared with depression (2.53-versus 1.8-fold) (13) , suggesting that bipolar depression continues to be prevalent even in those bipolar patients who benefit from lithium's antimanic effects. The treatment ofbipolar depression is particularly challenging, because the long-term safety of antidepressants in patients with manicdepressive illness is not established; in fact, accumulating evidence now suggests that antidepressants may function as mood-destabilizing agents for patients with bipolar disorder, actually worsening the course of illness (14) .
This pilot study empirically examines the acceptability and efficacy of cognitive-behaviour therapy (CBT) combined with mood-stabilizing medication for bipolar depression, compared with standard CBT for recurrent unipolar depression.
492
The Canadian Journal of Psychiatry Vol 44,No5 
Method

Treatment Intervention
Bipolar depressed patients completed a course of individual CBT that began 2 weeks after initial assessment. The CBT was delivered weekly for 20 weeks, based on the standard protocol (16, 17) , but modified according to Basco and Rush (18) to include specific techniques for bipolar patients. Unipolar depressed patients received the same course of treatment based on the standard protocol alone. All treatment was delivered by doctorate-level therapists. 
17-item Hamilton Depression Rating
Scale (HDRS-17), having at least grade 8 education, being fluent in English, and being able to provide informed consent. Exclusion criteria included being diagnosed with schizophrenia or schizoaffective disorder, substance abuse disorder, organic brain syndrome, or antisocial or borderline personality disorder. Bipolar patients were matched retrospectively by age and gender. Bipolar patients were unable to generate a discrete number of depressive episodes more accurate than "numerous," so all matched unipolar patients endorsed multiple depressive episodes prior to their index episode treatment with CBT. The control group therefore comprised patients suffering from recurrent unipolar depression. After a complete description of the study to the subjects, written informed consent was obtained.
Medication Results
Although being treated with antidepressant pharmacotherapy was an exclusion criteria for all study subjects, all bipolar patients were required to be treated with either lithium (n = 10) or an anticonvulsant mood stabilizer (n = 1). Blood levels were monitored, and lithium was maintained at 0.8-1.0 mmol/L (n = 10). Although recommended mood-stabilizing therapeutic blood levels for anticonvulsant medication still remain unclear (15) , carbamazepine blood levels were to be maintained at the arbitrary conventional antiepileptic range of 17-50 umol/ml (n = 0). Similarly, valproic acid levels were maintained at 350-700 umol/L (n = 1).
Measures
Diagnoses were derived from Schedule of Affective Disorders and Schizophrenia (SADS-L) interviews, as was information regarding age of onset, clinical course, and outcome. Subjects also completed the HDRS, Automatic Thoughts Questionnaire (ATQ), and Dysfunctional Attitude Scale (DAS) at pre-and posttreatment intervals, while the Beck Depression Inventory (BDI) was completed on a weekly basis. All assessments were performed by independent, nonblind, reliable master's degree-level psychology raters.
There were no statistically significant differences between the 2 patient groups on any ofthe matching variables:age, BD = 43.9 years, UD = 45.5 years; age of onset, BD = 24.9 years, UD = 24.9 years; average duration of present episode, BD = 6.6 months, UD = 8.4 months; gender, 6 females and 2males in each group; pretreatment HDRS, BD = 22.6, un = 16.2;
pretreatmentBDI, BD = 23.5, UD = 26.9. There were8bipolar (7 bipolar I, 1 bipolar II) depressed patients who completed treatment, while 3 dropped out. All of the dropout patients were bipolar I, and 1 ofthe 3 suffered fromrapid cycling. All ofthe subjects who dropped out terminatedtherapy before session 6 and were not included in the outcome analysis. The average patient with bipolar disorder had beenill for 11.9 years and scored 22.6 on the HDRS, consistent with moderate depressive symptomatology. The average bipolar patient experienced previous depressions ranging in length from 6 to 12 months, and these were typically treatedwith antidepressant medication combined with mood-stabilizing medication. Only 1 bipolar patient suffered from rapid cycling, and no patient met criteria for mixed mania. average, well over a 50% reduction on the HDRS. This level of improvement was comparable to that observed in the matched unipolar depressed group. Finally, although negative automatic thinking for the bipolar patient group was reduced, these patients' scores on the DAS did not decrease significantly following CBT, whereas the opposite was true for the unipolar depressed control subjects.
Discussion
To our knowledge, this is the first study ever to examine empiricallythe effects ofCBT on bipolar depression. In this pilot study, bipolar depressed patients treated with a combination of mood stabilizers and CBT accepted the treatment and showed a robust treatment response in the absence of antidepressant medication. The level ofimprovement observed was comparable to that observed in a control group of casematched recurrent unipolar patients treated with CBT alone. In addition, although manic and hypomanic symptoms have been noted during antidepressant pharmacotherapy of bipolar depression, we did not observe these features in our patient sample. Finally, despite improvement in depressive symptomatology and negative thinking, no significant changes were observed in underlying dysfunctional attitudes over the course of treatment. This suggests that bipolar depressed patients may require a more intensive course of CBT, perhaps between episodes, before emotional problem-solving and affect-regulation skills are accessible and can be reliably deployed. This conclusion is consistent with the experience of other researchers who have applied CBT to more severely ill patients within a continuation treatment framework (19) .
Obvious limitations of this study include the small sample size and the lack of a bipolar control group (depressed patients receiving either standard antidepressant treatment or no specific antidepressant treatment except for a moodstabilizer regimen). Although the clinical validity ofcomparing bipolar depressed patients with a unipolar depressed group might be questionable (20) , our study's 2 groups were comparable on age of onset, length of illness, and duration of thepresent episode. Both groups also reported multiple previous affective episodes. In addition, our bipolar sample showed a slightly higher level ofseverity ofdepression on the HDRS although not on the more subjective BDI. Also, our study lacked uniform standardization of the mood-stabilizer treatment, which would have improved the generalizability of the results. That said, it is noteworthy that compliance with mood-stabilizing medication already appeared to be optimal at the baseline assessment (levels 0.8-1.0). However, because complete data were not available on plasma levels at endpoint, we cannot be sure that better medication adherence did not playa role in the results reported. Future research should investigate this possible effect more carefully. Finally, it should be noted that our present bipolar sample was relatively homogeneous, since only 2 members suffered from rapid cycling and bipolar type II, and all patients, except 1, were treated with lithium monotherapy. Because CBT emphasizes the acquisition of emotional problem-solving skills, it is quite labour-intensive and requires that patients possess insight, motivation, and the capacity to concentrate. This may limit its applicability to a more heterogeneous bipolar population. Nevertheless, these preliminary findings warrant further investigation to determine whether the effects of short-term adjunctive CBT for bipolar depression are replicable in larger controlled studies and also durable over a longer course of time.
Clinical Implications
• Patients with bipolar depression appeared to respond to adjunctive short-term cognitive-behaviour therapy (CBT) in a manner comparable to matched unipolar patients. These results are promising for more rigorously evaluating CBT in the treatment of bipolar depression. • Bipolar patients' deeper dysfunctional cognitive style did not respond as robustly to short-term CBT as did unipolar patients, suggesting that a longer course ofCBT may be necessary.
Limitations
• Lack ofa bipolar control group limits conclusions about CBT's efficacy for this population. • Small sample size and homogeneity of the bipolar patient sample limits generalizability of the study results.
